Skip to main content

MRSA Led Surge in Pediatric Staphylococcus Hospitalizations


A more than 10-fold increase in methicillin-resistantStaphylococcus aureus (MRSA) infections drove a surge in pediatric Staphylococcus-associated hospitalizations that peaked in 2006, according to an analysis of 25 years of pediatric hospital discharge data in California. The study, published online December 12 in Emerging Infectious Diseases, found that children hospitalized for staphylococcal infections had longer hospital stays and higher mortality risk than children hospitalized for other causes.
Kathleen Gutierrez, MD, associate professor, Stanford University School of Medicine, California, and colleagues examined the hospital discharge data from 1985 to 2009 for 140,265 children and found that the number of staphylococcal infections rose from 49 per 100,000 children to a peak of 83 per 100,000 children in 2006 before falling to 73 per 100,000 in 2009. The records came from the California Office of Statewide Health Planning and Development, which maintains a hospital discharge database.
MRSA and cellulitis drove the increase in staphylococcal infections: From 2000 to 2009, MRSA-related hospitalizations increased from 3 per 100,000 to 35 per 100,000 children, with MRSA cellulitis making up 46% of the MRSA-related hospitalizations, MRSA pneumonia making up 6%, and MRSA septicemia making up 4.5%.
Mean length-of-stay (LOS) also increased in peak infection years, from 17.3 days to 26.7 days between 1985 and 2002; by 2009, the mean fell again to 17.7 days.
Among non-neonates, children with hospital-onset (HO) infections were at the highest risk for death from staphylococcal infection. Only 5 in 100,000 children had an HO infection; however, 7.5% of those infections were fatal. The LOS was also longest at 40.7 days (median, 28 days). Twenty infections per 100,000 children were community onset (CO), and 20 per 100,000 were community-onset, healthcare-associated (CO-HCA) infections. Children with CO-HCA infections died 2% of the time, with a mean LOS of 13.6 days (median, 8 days). Children with CO infections had the lowest fatality rate, at less than 0.1%, with a mean LOS of 5.3 days (median, 4 days).
Children younger than 3 years, black children, boys, and children without private insurance had the highest incidence of hospitalization with staphylococcal infection. The researchers found black children were 1.5 times more likely to be hospitalized for a staphylococcal infection than white children, and Asian children were 0.6 times less likely to be hospitalized compared with white children. Black and Asian children had the highest mortality percentage, at 2.9%, compared with 2.3% for white children and 2.4% for Hispanic children.
Lack of Insurance Cited
Lack of insurance was the most predictive factor in increasing risk for staphylococcal infection among hospitalized children (odds ratio [OR], 1.3). By comparison, race was associated with an OR of 1.05 for black children, an OR of 0.96 for Hispanic children, and an OR of 1.0 for Asian children compared with white children.
Children without private insurance also had slightly longer LOS (median, 8 days) than those with insurance (median, 7 days).
Children younger than 1 year were most likely to be hospitalized, at a rate of 452 children hospitalized per 100,000 children. Neonates (infants <30 days old) made up 25% of the entire infected population with an OR for infection of 5.64 (95% confidence interval [CI], 5.55 - 5.73) compared with a reference group of children aged between 1 and 2 years. Some 4.5% of neonates died, the highest percentage of fatalities in all age categories.
The median hospital stay among all children was 7 days, with stays ranging up to 2067 days. In 10% of cases, children remained hospitalized less than 60 days. Neonates had longest LOS, with a median of 28 days.
Sixty-five percent of the children hospitalized for 3 months or longer were neonates hospitalized within 2 days of birth, even though neonates made up just 16% of the infected population.
When neonates were removed from calculations, staphylococcus remained a primary driver of LOS. Excluding neonates, children hospitalized for staphylococcal infections stayed in the hospital longer than children hospitalized for any other reason (median LOS for staphylococcal-infected children was 6 days [mean, 13.9] compared with 2 days [mean, 4.9] for all other causes).
Children with a staphylococcal infection were more likely to die than those hospitalized for any other diagnosis (OR, 2.1; 95% CI, 2.0% - 2.2%) after controlling for year of admission, LOS, age at admission, sex, race, and insurance status. The infection was fatal in 2.5% of children, but most (82.6%) had a routine discharge. Another 10.4% required low- to medium-intensity care on discharge, and 4.4% were transferred to another acute-care facility. Over the study period, risk for death increased for children hospitalized with staphylococcal infections, going from 2.4% in 1985 to 3.5% in 2002 and then falling again in 2003 and remaining below 2% from 2006 to 2009.
The authors have disclosed no relevant financial relationships.

Comments

Popular posts from this blog

Contact Precautions May Have Unintended Consequences

Contact precautions, including gloves, gowns, and isolated rooms, have helped stem the transmission of hospital pathogens but have also had some negative consequences, according to findings from a new study. Healthcare worker (HCWs) visited patients on contact precautions less frequently than other patients and spent less time with those patients when they did visit, report Daniel J. Morgan, MD, from the University of Maryland School of Medicine and the Veterans Affairs (VA) Maryland Health Care System, Baltimore, and colleagues. Moreover, patients on contact precautions also received fewer outside visitors. "Less contact with HCWs suggests that other unintended consequences of contact precautions still exist," Dr. Morgan and coauthors write. "The resulting decrease in HCW contact may lead to increased adverse events and a lower quality of patient care due to less consistent patient monitoring and poorer adherence to standard adverse event prevention methods (such...

Antidepressants Linked to Higher Diabetes Risk in Kids

Pediatric patients who use antidepressants may have an elevated risk for type 2 diabetes, the authors of a new study report. In a retrospective cohort study of more than 119,000 youths 5 to 20 years of age, the risk for incident type 2 diabetes was nearly twice as high among current users of certain types of antidepressants as among former users, Mehmet Burcu, PhD, and colleagues report in an article  published online October 16 in  JAMA Pediatrics . The risk intensified with increasing duration of use, greater cumulative doses, and higher daily doses of these antidepressants. The findings point to a growing need for closer monitoring of these products, including greater balancing of risks and benefits, in the pediatric population, the authors caution. They undertook the study because, despite growing evidence of an association between antidepressant use and an increased risk for type 2 diabetes in adults, similar research in pediatric patients was scarce. "To our know...

Missing Data Lead FDA Panel to Vote Against Rivaroxaban for ACS May 23, 2012 (Updated May 24, 2012) (Silver Spring, Maryland) — The missing data issues plaguing the ATLAS ACS 2 TIMI 51 trial of the factor Xa inhibitor rivaroxaban (Xarelto, Bayer Healthcare/Janssen Pharmaceuticals) have prevented the drug from earning the endorsement of the FDA Cardiovascular and Renal Drugs Advisory Committee. At its May 23 meeting, the panel voted six to four (with one abstention) against recommending that the FDA approve rivaroxaban for reducing the risk of thrombotic cardiovascular events in patients with acute coronary syndrome or unstable angina in combination with aspirin, aspirin plus clopidogrel, or ticlopidine. Janssen's application is based on the results of the ATLAS ACS 2 phase 3 and the ATLAS ACS TIMI 46 phase 2 trial. The placebo-controlled ATLAS ACS 2 showed rivaroxaban reduced the risk of both all-cause and cardiovascular mortality while increasing the risk of bleeding and intracranial hemorrhage, but the studies were hindered by early patient withdrawals and missing data. We Don't Know What We're Missing Based on the ATLAS ACS 2 results, FDA reviewer Dr Karen Hicks recommended approval of rivaroxaban for the requested indications except all-cause mortality. However, another FDA reviewer, Dr Thomas Marciniak, was adamant that the trial results are not interpretable because about 12% of the patients had incomplete follow-up, far higher than the 1% to 1.5% differences in the end-point rates between rivaroxaban and placebo. A total of 1294 subjects discontinued the trial prematurely, and the company was only able to contact 183, of which 177 were confirmed to be alive. Because of the patient dropouts, the company adopted a "modified intention-to-treat analysis," whereby patients were observed for 30 days after randomization or the global end date for the trial, instead of observing all the patients until the end of the trial as the FDA originally suggested. Marciniak criticized the sponsor's efforts to follow the patients and said that three patient deaths not counted in the modified intention-to-treat analysis may just be the "tip of the iceberg." Because the percentage of patients whose ultimate vital status remains unknown is much greater than the reported differences in mortality rates, the claimed mortality benefits are not reliable. The majority of the panel sided with Marciniak. For example, Dr Sanjay Kaul (University of California, Los Angeles) voted "no" because "there was enough uncertainty in the quality and robustness of the data that dissuaded me from voting yes. . . . The 'missingness' of the data doesn't invalidate it, but it certainly makes it hard to infer [the conclusion]." Dr Steven Nissen (Cleveland Clinic, OH) said that the decision to use the modified intention-to-treat analysis had a "profound impact" on the interpretability of the data. "It's saying we don't care what happens after 30 days, [and] that colored the trial in ways we couldn't recover from." Given the risk of major bleeding, "I want to see better evidence that this strategy of adding an Xa inhibitor or a direct thrombin inhibitor or something else to a good antiplatelet agent is robustly better for the patient," Nissen said. He recommends that the companies run a new trial of the 2.5 twice-daily dose of rivaroxaban using a strict intention-to-treat approach, but, he said, "I don't expect the death benefit to be too robust." Several panelists said they were concerned that the patients who dropped out of the trial were disproportionately likely to have a bleeding event, which led them to quit the trial, or a "protopathic" event, as statistician Dr Scott Emerson (University of Washington, Seattle) put it. "We're worried that an impending event is what is changing their behavior. We see that all the time in clinical trials--that regularly measured end points do not pick up [all of] the events," he said. He said that since the company was only able to contact 183 of the over 1200 patients who dropped out, it is possible that the dropouts skew the outcomes comparison of the trial. "Differential event rates after dropout are the number-one thing we're afraid of, so you have to explore it" in a statistical sensitivity analysis of the potential impact of these unknown outcomes. "It would not surprise me if, at the end of the day, these data did not hold up under a proper sensitivity analysis," he said. "What I want to know is, among the people who had events, how differential was the follow-up, but I can tell you by just looking at it, there was a very slightly different amount of follow-up of the people in the treatment arm. But I don't know whether everyone in the treatment arm was cured and they were trekking in the Himalayas and everyone in the placebo arm went home to die. I don't know that that's not the case." Dr Maury Krantz (University of Colorado, Denver) voted in favor of approval but said he does not know how rivaroxaban would perform in general clinical practice, especially when used with aspirin and clopidogrel. "I felt very much torn by this. This isn't a simple paradigm shift. It means going to triple therapy, which is really a three-headed monster in many ways. I think that what you're going to see in practice, if this is not done carefully with the proper labeling and secondary studies, is really dramatic magnification of bleeding and perhaps minimization of the efficacy benefit."

May 23, 2012   (Updated May 24, 2012)  (Silver Spring, Maryland)  —  The missing data issues plaguing the  ATLAS ACS 2 TIMI 51   trial of the factor Xa inhibitor  rivaroxaban  (Xarelto, Bayer Healthcare/Janssen Pharmaceuticals) have prevented the drug from earning the endorsement of the  FDA  Cardiovascular and Renal Drugs Advisory Committee. At its May 23 meeting , the panel voted six to four (with one abstention) against recommending that the FDA approve rivaroxaban for reducing the risk of thrombotic cardiovascular events in patients with acute coronary syndrome or unstable angina in combination with aspirin, aspirin plus  clopidogrel , or  ticlopidine . Janssen's application is based on the results of the ATLAS ACS 2 phase 3 and the  ATLAS ACS TIMI 46   phase 2 trial. The placebo-controlled ATLAS ACS 2 showed rivaroxaban reduced the risk of both all-cause and cardiovascular mortality while increasing the ri...